Talk:Farletuzumab

Phase III trial reported in 2016
J Clin Oncol. 2016 Jul 1;34(19):2271-8. doi: 10.1200/JCO.2015.63.2596. Epub 2016 Mar 21. A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse. Results of trial were negative for population as a whole, some evidence that a subset responded favorably. This article should be updated. David notMD (talk) 16:02, 6 October 2019 (UTC)